Receptor activator of nuclear factor kappa B ligand is an important cytokine involved in osteoclast activation; denosumab, a fully human monoclonal antibody to this molecule, has finished a major fracture trial.
New therapies such as the antibody to RANKL (denosumab) are undergoing phase III clinical testing.
.
